🇺🇸 FDA
Pipeline program

CS-1103

CS-1103-01

Phase 1 small_molecule completed

Quick answer

CS-1103 for Substance Use Disorders is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Substance Use Disorders
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials